Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2006

View Archived Issues

YM-341619: novel STAT-6 inhibitor with efficacy against allergy

University of Arizona presents a novel bifunctional opioid agonist/NK-1 antagonist

Antiendotoxic effects of a novel polymyxin B analogue

Evidence connects chemokines and their receptors with lung metastasis

Alnylam's pandemic influenza research boosted by NIAID grant

Intercell and Path team up for S. pneumoniae vaccine

SBIR grant for Cleveland BioLabs' radioprotector research

MethylGene report on enhanced potency of second generation MGCD-0103 analogues

Artisan Pharma formed through financing and compound inlicensing

p53/p21 status regulates the response to VX-680

Italian researchers present a novel selective muscarinic M3 receptor antagonist

Dual dopamine D2/D3 receptor ligand described with antipsychotic efficacy

European orphan designation for Advexin in Li-Fraumeni syndrome

Ipsen and GTx sign European agreement for Acapodene rights

Phase IIb studies in Denmark to assess BP-C1 for breast cancer

Taisho and Tokuhon collaborate on antiinflammatory analgesic patch in Japan

Takara Bio offers RetroNectin for phase I CLL trials

AnGes plans atopic dermatitis trial for NF-kappaB decoy oligodeoxynucleotide

Northwest cleared for phase I study of DCVax-LB in NSCLC

Xoma successfully reformulates XOMA-629 for acne

New ARIES-3 study investigates ambrisentan in pulmonary hypertension

Chelsea seeks orphan drug status, forms scientific advisory board for droxidopa

Teverelix LA shows potential for endometriosis

Novel antiinfective agents disclosed in recent patent literature

Symlin improves diabetes control in study

Recent patents disclose new therapeutic agents for depression, insomnia

Novel diagnostic agents emerge from Mallinckrodt R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...